27.09.2017 Formal opening of first production lines of the production plant that will manufacture single-use three component syringes!
The formal opening of PASCAL MEDICAL’s production plant intended for manufacturing single-use medical devices took place on September 27, 2017 in the territory of Dubna Special Economic Zone. The Governor of Moscow region Andrey Vorobyev gave the go-ahead to production. An agreement for construction of this high tech production facility was signed with the investor during the Saint Petersburg Economic Forum in 2016. Currently the first block of production lines are put into operation and three more are planned for launching in future. The plant manufactures the full range of single-use injection syringes, including insulin and tuberculin syringes. Production capacity of the plant is 450 million pieces of products per year.
The main feature of PASCAL MEDICAL is responsibility for quality of its products. Quality control on each stage of production and organization of work of each employee are aimed at achieving the main goal of the plant, which is to destroy the myth of low quality of domestic products and to build up trust in Russian manufacturers by offering consumers a product that complies with international standards of quality and matches similar foreign products in every aspect.
“When our plant becomes operational, total production capacity of existing Russian manufacturers of single-use syringes will be able to completely satisfy domestic demand for such products, though a share of imported products still remains very high. Now the main goal is to improve quality of Russian-made medical devices, including by implementation of quality management systems at enterprises and by enhancing efficiency of quality certification processes. Russian government and, in particular the Federal Service for Supervision of Healthcare and Social Development, already named such improvements as one of their priorities. This will allow Russian-made products to have a major share on our medical market and fully implement the government’s the policy relating to replacement of imported goods. And our new state of the art production lines operating in compliance with GMP can significantly contribute to success of this process,” said Alexander Fedorov, the general director of PASCAL MEDICAL.
